ALKS vs NMRA
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. NMRA: Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
Side-by-side fundamentals
| Metric | ALKS | NMRA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $52.73 | $1.61 | |
| Market cap as of 2026-08-03 | $8.8B | $298M | |
| P/E as of 2026-08-03 | 53.82 | n/a | |
| PEG as of 2026-08-03 | -19.70 | n/a | |
| Net margin as of 2026-08-03 | +9.8% | n/a | |
| Gross margin as of 2026-08-03 | +86.6% | n/a | |
| Operating margin as of 2026-08-03 | +12.3% | n/a | |
| ROE as of 2026-08-03 | +8.8% | -181.7% | ALKS higher |
| ROA as of 2026-08-03 | +5.4% | -119.2% | ALKS higher |
| Debt / equity as of 2026-08-03 | 0.86 | 0.75 | NMRA lower |
| Revenue growth (YoY) as of 2026-08-03 | +3.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.9% | n/a | |
| Beta as of 2026-08-03 | 0.26 | 1.30 | |
| 1-year return as of 2026-07-27 close | +101.8% | -17.9% | ALKS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.